CollPlant Biotechnologies approves 1-for-10 reverse share split for Nasdaq compliance
- CollPlant Biotechnologies approved a one-for-ten reverse share split
- Split effective when Nasdaq Capital Market opens on September 4, 2026
- Shares will trade under existing ticker symbol CLGN on adjusted basis
- Move aims to regain compliance with Nasdaq minimum bid price requirement
- Shareholders approved action at meeting held on August 18, 2026
*this image is generated using AI for illustrative purposes only.
CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) approved a one-for-ten reverse share split to regain compliance with Nasdaq listing requirements. The action follows shareholder approval at an extraordinary general meeting.
The Board of Directors approved the reverse split, which is scheduled to take effect when the Nasdaq Capital Market opens on September 4, 2026. At that time, ordinary shares will begin trading on a split-adjusted basis under the existing ticker symbol "CLGN".
Shareholder Approval and Strategic Context
Shareholders granted approval for the reverse split at the Extraordinary General Meeting held on August 18, 2026. The Board stated that the reverse split is being implemented as part of the company's strategic plan to regain compliance with the Nasdaq minimum bid price requirement for continued listing.
No financial performance metrics were disclosed in the announcement regarding revenue, profit, or balance sheet positions.
What specific operational or financial milestones must CollPlant achieve to sustain compliance with Nasdaq listing requirements post-split?
How might the one-for-ten reverse split impact the liquidity and trading volume of CLGN shares among retail and institutional investors?
Are there any pending strategic partnerships, product launches, or capital raise initiatives that CollPlant is leveraging to support its share price recovery?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
